A Study of the Safety and Effectiveness of Experimental Elezanumab for Progressive Forms of Multiple Sclerosis
Logo Image
"Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!"
Age: 18 to 65 years old
Gender:
Any
Healthy Volunteers: No
Keywords: multiple sclerosis, progressive multiple sclerosis
Type: Drug study, Phase 2
Target:
6 Participants
Investigator:
Description
The purpose of this study is to test the investigational study drug, elezanumab. We will test if elezanumab is safe and effective. It will be added to standard treatment in adults with progressive forms of multiple sclerosis (PMS).

Investigational means that the study drug has not been approved for sale by the FDA. It is being studied to determine if it will improve physical functioning in patients with progressive forms of MS who have disability.
This study requires

The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.

Who can participate

Inclusion criteria:

  • Subject has diagnosis of primary-progressive multiple sclerosis (PPMS) or non-relapsing secondary-progressive multiple sclerosis (SPMS) and no relapses for at least 24 months
  • Subject has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test

Exclusion criteria:

  • Treatment with any of the following within the 6 months prior to Screening: natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; intravenous immunoglobulin (IVIg); any interferon product; and intravenous (IV), oral, or intrathecal corticosteroids for the purposes of disease modification
  • Treatment with the following within 1 year prior to Screening: cyclophosphamide or alemtuzumab
Benefits and risks of participating
BENEFITS:

We cannot promise any benefits to you as a result of taking part in this research study.


RISKS:

The study doctor will discuss the risks associated with taking part in this research study.
Compensation
If you agree to take part in this research study, we will compensate you $100 for each study visit you complete, which includes coverage of local travel expenses such as meals and mileage. This could total up to $1700 if you complete all study visits. In the event that an unscheduled visit is conducted, you may be paid $40 for the completion of that visit.
Resources
Schedule
Study duration and period
We expect that you will be in this research study for 18-19 months (about a year and a half), plus time for screening (up to 4 weeks).
Recruitment period
From Aug. 15, 2019
Location
UC Davis Medical Center
2315 Stockton Boulevard
Sacramento, CA 95817
Research Topic
Conditions:
  • Multiple Sclerosis (MS)

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview